AgomAb Therapeutics NV American Depositary Shares Net Assets
AgomAb Therapeutics NV American Depositary Shares net assets. Based on the latest financial reports, AgomAb Therapeutics NV American Depositary Shares (AGMB) has net assets worth $146.93 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($165.63 Million) and total liabilities ($18.70 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See net asset quality index of AgomAb Therapeutics NV American Deposita to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $146.93 Million |
| % of Total Assets | 88.71% |
| Annual Growth Rate | 32.58% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 57.52 |
Net Assets of AgomAb Therapeutics NV American Depositary Shares (2021–2025)
Net assets of AgomAb Therapeutics NV American Depositary Shares from 2021 to 2025. This chart illustrates how AgomAb Therapeutics NV American Depositary Shares's net assets have evolved over time, based on quarterly financial data. Also explore how fast is AgomAb Therapeutics NV American Deposita growing its equity to track the company's year-over-year net asset growth rate.
Annual Net Assets for AgomAb Therapeutics NV American Depositary Shares (2021–2025)
The table below shows the annual net assets of AgomAb Therapeutics NV American Depositary Shares from 2021 to 2025. For live market cap and overall valuation, see AgomAb Therapeutics NV American Deposita stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $130.90 Million | -30.40% |
| 2024-12-31 | $188.08 Million | +24.20% |
| 2023-12-31 | $151.44 Million | +128.59% |
| 2022-12-31 | $66.25 Million | +56.38% |
| 2021-12-31 | $42.36 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to AgomAb Therapeutics NV American Depositary Shares's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 13689700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
AgomAb Therapeutics NV American Depositary Shares Net Assets Breakdown (December 2025)
AgomAb Therapeutics NV American Depositary Shares net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $312.62 Million | 238.82% |
| Total Equity | $130.90 Million | 100.00% |
AgomAb Therapeutics NV American Depositary Shares Competitors by Market Cap
The table below lists competitors of AgomAb Therapeutics NV American Depositary Shares ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Northeast Community Bancorp Inc
NASDAQ:NECB
|
$368.93 Million |
|
Focus Minerals Ltd
AU:FML
|
$369.02 Million |
|
Analyst IMS Investment Management Services Ltd
TA:ANLT
|
$369.09 Million |
|
SVI Public Company Limited
BK:SVI
|
$369.13 Million |
|
Aprogen KIC Inc
KO:007460
|
$368.86 Million |
|
China Lilang Limited
F:5LX
|
$368.83 Million |
|
Kretam Holdings Bhd
KLSE:1996
|
$368.78 Million |
|
Jinsanjiang (Zhaoqing) Silicon Material Company Limited
SHE:301059
|
$368.69 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in AgomAb Therapeutics NV American Depositary Shares's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 188,081,000 to 130,902,000, a change of -57,179,000 (-30.4%).
- Net loss of 46,267,000 reduced equity.
- Other factors decreased equity by 10,912,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-46.27 Million | -35.34% |
| Other Changes | $-10.91 Million | -8.34% |
| Total Change | $- | -30.40% |
Book Value vs Market Value Analysis
This analysis compares AgomAb Therapeutics NV American Depositary Shares's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.07x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 4.10x to 2.07x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | $1.83 | $7.49 | x |
| 2023-12-31 | $4.18 | $7.49 | x |
| 2024-12-31 | $5.19 | $7.49 | x |
| 2025-12-31 | $3.61 | $7.49 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently AgomAb Therapeutics NV American Depositary Shares utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -35.34%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.17x
- Recent ROE (-35.34%) is below the historical average (-19.94%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | -12.29% | 0.00% | 0.00x | 1.52x | $-14.77 Million |
| 2023 | -7.52% | 0.00% | 0.00x | 1.13x | $-26.53 Million |
| 2024 | -24.60% | 0.00% | 0.00x | 1.10x | $-65.08 Million |
| 2025 | -35.34% | 0.00% | 0.00x | 1.17x | $-59.36 Million |
Industry Comparison
This section compares AgomAb Therapeutics NV American Depositary Shares's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $126,960,080
- Average return on equity (ROE) among peers: -97.16%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| AgomAb Therapeutics NV American Depositary Shares (AGMB) | $146.93 Million | -12.29% | 0.13x | $368.87 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $29.61 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $4.06 Million | -282.32% | 0.21x | $248.75 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $15.18 Million |
| Abpro Holdings, Inc. (ABP) | $-75.73 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $189.45 Million | -60.80% | 0.14x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $59.19 Million | -23.76% | 0.21x | $834.03 Million |
| ABVC Biopharma Inc (ABVC) | $13.30 Million | -59.47% | 0.58x | $26.65 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $7.56 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $17.86 Million | -80.65% | 0.23x | $3.55 Billion |
About AgomAb Therapeutics NV American Depositary Shares
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinica… Read more